Last reviewed · How we verify
RhIGF-1
At a glance
| Generic name | RhIGF-1 |
|---|---|
| Also known as | Increlex, Mecasermin (brand name Increlex) |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Patent ductus arteriosus
- Anaemia neonatal
- Hypoglycaemia
- Retinopathy of prematurity
- Bronchopulmonary dysplasia
- Injection site hypertrophy
- Jaundice neonatal
- Neonatal respiratory distress syndrome
- Infantile apnoeic attack
- Headache
- Hyperglycaemia
- Tonsillar hypertrophy
Key clinical trials
- Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors (PHASE1, PHASE2)
- IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency (PHASE1, PHASE2)
- Long-Term Treatment With rhIGF-1 in GHIS (PHASE2, PHASE3)
- rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency (PHASE2)
- Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP) (PHASE2)
- Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents (PHASE1, PHASE2)
- Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa (PHASE2)
- Effects of Anorexia Nervosa on Peak Bone Mass (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RhIGF-1 CI brief — competitive landscape report
- RhIGF-1 updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI